Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 27Ovarian Neoplasms 16Endometrial Neoplasms 16Breast Neoplasms 16Triple Negative Breast Neoplasms 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14Lung Neoplasms 13Fallopian Tube Neoplasms 12Squamous Cell Carcinoma of Head and Neck 9Neoplasm Metastasis 7Carcinoma 5Stomach Neoplasms 4Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Peritoneal Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Esophageal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Ovarian Epithelial 3Adenocarcinoma 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2Melanoma 2Lung Diseases 2Hypopharyngeal Neoplasms 2

Interventions

Oxaliplatin 7Fluorouracil 7pembrolizumab 6Leucovorin 5Specimen Handling 4Cisplatin 4Capecitabine 4patritumab deruxtecan 3Trastuzumab 3Radiation 3Paclitaxel 3Nivolumab 3durvalumab 2Surgical Procedures, Operative 2Ramucirumab 2Radiotherapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Irinotecan 2Immunotherapy 2Exercise 2Drug Therapy 2Carboplatin 2zolbetuximab 1zanidatamab 1ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Paclitaxel × 30 days × Clear all
NCT05319730 2026-05-26

MK-3475-06B

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
230 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡